TY - JOUR
T1 - Screening for vitamin D deficiency: defining vitamin D deficiency, target thresholds of treatment and estimating the benefits of treatment
AU - Glendenning, Paul
AU - Inderjeeth, Charles
PY - 2012
Y1 - 2012
N2 - Vitamin D sufficiency has been associated with improved health outcomes but cost benefit analyses of published data adopt a number of assumptions. Firstly, definitions of vitamin D deficiency vary Secondly, available methods used for the analysis of 25-hydroxyvitamin D (25OHD) have significant limitations which could affect the adoption of specific target thresholds for treatment. Thirdly, although a variety of diseases are associated with vitamin D deficiency, randomised clinical trial data demonstrating the benefit of vitamin D supplementation only exist for the prevention of falls or fractures. This review will summarise the current evidence regarding an appropriate target threshold of 25OHD and review proposed therapeutic target thresholds of treatment. The limitations of current methods will be reviewed and objective data relating to the costs of diagnosis, the costs of treatment, and the level of evidence that screening could lessen disease burden in the community, will be provided. Finally, information needed by governments and health organisations to help justify population screening and what strategies could be adopted to make screening more cost-effective will be explored.
AB - Vitamin D sufficiency has been associated with improved health outcomes but cost benefit analyses of published data adopt a number of assumptions. Firstly, definitions of vitamin D deficiency vary Secondly, available methods used for the analysis of 25-hydroxyvitamin D (25OHD) have significant limitations which could affect the adoption of specific target thresholds for treatment. Thirdly, although a variety of diseases are associated with vitamin D deficiency, randomised clinical trial data demonstrating the benefit of vitamin D supplementation only exist for the prevention of falls or fractures. This review will summarise the current evidence regarding an appropriate target threshold of 25OHD and review proposed therapeutic target thresholds of treatment. The limitations of current methods will be reviewed and objective data relating to the costs of diagnosis, the costs of treatment, and the level of evidence that screening could lessen disease burden in the community, will be provided. Finally, information needed by governments and health organisations to help justify population screening and what strategies could be adopted to make screening more cost-effective will be explored.
U2 - 10.1097/PAT.0b013e32834e8df6
DO - 10.1097/PAT.0b013e32834e8df6
M3 - Article
VL - 44
SP - 160
EP - 165
JO - Pathology
JF - Pathology
SN - 0031-3025
IS - 2
ER -